Cargando…
A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted
Previous studies of SARS-CoV-2 viral infection suggest that both the humoral and cytotoxic arms of the immune system are weak in patients with severe COVID-19 disease when compared to mild disease. A cytokine storm is also induced in severe disease. IL-15 has been shown to support the cytotoxic arm...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583616/ https://www.ncbi.nlm.nih.gov/pubmed/33199178 http://dx.doi.org/10.1016/j.cytogfr.2020.10.005 |
_version_ | 1783599427964895232 |
---|---|
author | Wilz, Stephen W. |
author_facet | Wilz, Stephen W. |
author_sort | Wilz, Stephen W. |
collection | PubMed |
description | Previous studies of SARS-CoV-2 viral infection suggest that both the humoral and cytotoxic arms of the immune system are weak in patients with severe COVID-19 disease when compared to mild disease. A cytokine storm is also induced in severe disease. IL-15 has been shown to support the cytotoxic arm of the immune response. IL-21 has been shown to support both the cytotoxic and humoral arms of the immune response. In addition, in some settings, Il-21 has been shown to actually decrease IL-6 and TNF-alpha production, reducing the inflammatory proteins involved in the cytokine storm. Furthermore, in other settings, the combination of IL-15 and IL-21 has been shown to be more effective than either interleukin alone in promoting an effective immune response. Therefore, a clinical trial that examines the use of the combination of IL-15 and IL-21 for COVID-19 patients is warranted. |
format | Online Article Text |
id | pubmed-7583616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75836162020-10-26 A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted Wilz, Stephen W. Cytokine Growth Factor Rev Article Previous studies of SARS-CoV-2 viral infection suggest that both the humoral and cytotoxic arms of the immune system are weak in patients with severe COVID-19 disease when compared to mild disease. A cytokine storm is also induced in severe disease. IL-15 has been shown to support the cytotoxic arm of the immune response. IL-21 has been shown to support both the cytotoxic and humoral arms of the immune response. In addition, in some settings, Il-21 has been shown to actually decrease IL-6 and TNF-alpha production, reducing the inflammatory proteins involved in the cytokine storm. Furthermore, in other settings, the combination of IL-15 and IL-21 has been shown to be more effective than either interleukin alone in promoting an effective immune response. Therefore, a clinical trial that examines the use of the combination of IL-15 and IL-21 for COVID-19 patients is warranted. The Author. Published by Elsevier Ltd. 2021-04 2020-10-23 /pmc/articles/PMC7583616/ /pubmed/33199178 http://dx.doi.org/10.1016/j.cytogfr.2020.10.005 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Wilz, Stephen W. A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted |
title | A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted |
title_full | A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted |
title_fullStr | A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted |
title_full_unstemmed | A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted |
title_short | A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted |
title_sort | clinical trial of il-15 and il-21 combination therapy for covid-19 is warranted |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583616/ https://www.ncbi.nlm.nih.gov/pubmed/33199178 http://dx.doi.org/10.1016/j.cytogfr.2020.10.005 |
work_keys_str_mv | AT wilzstephenw aclinicaltrialofil15andil21combinationtherapyforcovid19iswarranted AT wilzstephenw clinicaltrialofil15andil21combinationtherapyforcovid19iswarranted |